Weight approximation in stroke before thrombolysis: the WAIST-Study: a prospective observational "dose-finding" study.

Background and Purpose: Because of the narrow therapeutic range for thrombolysis in stroke, accurate weight-based dosing is essential for efficacy and safety. Stroke patients are frequently incapable to communicate their correct body weight (BW). Thus, dosing is often based on BW estimation, which m...

Full description

Bibliographic Details
Published in:Stroke (00392499) Vol. 41; no. 12; pp. 2867 - 2872
Main Authors: Breuer L, Nowe T, Huttner HB, Blinzler C, Kollmar R, Schellinger PD, Schwab S, Köhrmann M, Breuer, Lorenz, Nowe, Tim, Huttner, Hagen B, Blinzler, Christian, Kollmar, Rainer, Schellinger, Peter D, Schwab, Stefan, Köhrmann, Martin
Format: research Journal Article
Published: Lippincott Williams & Wilkins Dec2010
Online Access:View this record in EBSCOhost
fields @attributes:
  recordID: 1
pdfLink:
plink: https://search.ebscohost.com/login.aspx?direct=true&db=ccm&AN=104955301&site=ehost-live
header:
  @attributes:
    shortDbName: ccm
    uiTerm: 104955301
    longDbName: CINAHL Complete
    uiTag: AN
  controlInfo:
    bkinfo:
    dissinfo:
    jinfo:
      jid:
        00392499
        1FT
      jtl: Stroke (00392499)
      issn: 00392499
      maglogo: N
    pubinfo:
      dt: Dec2010
      vid: 41
      iid: 12
      pid: 433
      pub: Lippincott Williams & Wilkins
      place: Baltimore, Maryland
    artinfo:
      ui:
        104955301
        104955301
        NLM21071723
        2010872705
        10.1161/STROKEAHA.110.578062
        NLM21071723
        104955301
      ppf: 2867
      ppct: 5
      formats:
      tig:
        atl: Weight approximation in stroke before thrombolysis: the WAIST-Study: a prospective observational "dose-finding" study.
      aug:
        au:
          Breuer L
          Nowe T
          Huttner HB
          Blinzler C
          Kollmar R
          Schellinger PD
          Schwab S
          Köhrmann M
          Breuer, Lorenz
          Nowe, Tim
          Huttner, Hagen B
          Blinzler, Christian
          Kollmar, Rainer
          Schellinger, Peter D
          Schwab, Stefan
          Köhrmann, Martin
        affil: Department of Neurology, University of Erlangen-Nuremberg, Schwabachanlage 6, 91054 Erlangen, Germany
      sug:
        subj:
          Body Weight Physiology
          Fibrinolytic Agents Administration and Dosage
          Fibrinolytic Agents Therapeutic Use
          Stroke Drug Therapy
          Tissue Plasminogen Activator Administration and Dosage
          Tissue Plasminogen Activator Therapeutic Use
          Aged
          Analysis of Variance
          Anthropometry
          Cerebral Hemorrhage Chemically Induced
          Cerebral Hemorrhage Epidemiology
          Data Analysis, Statistical
          Dose-Response Relationship, Drug
          Female
          Fibrinolytic Agents Adverse Effects
          Human
          Injections, Intravenous
          Male
          Treatment Errors
          Middle Age
          Odds Ratio
          Prospective Studies
          Risk Factors
          Tissue Plasminogen Activator Adverse Effects
          Treatment Outcomes
          Aged: 65+ years
          Middle Aged: 45-64 years
          Female
          Male
      ab: Background and Purpose: Because of the narrow therapeutic range for thrombolysis in stroke, accurate weight-based dosing is essential for efficacy and safety. Stroke patients are frequently incapable to communicate their correct body weight (BW). Thus, dosing is often based on BW estimation, which may lead to dosing errors. The aim of our study was to evaluate availability of BW information, accuracy of estimations, and final dosing of Alteplase (tissue plasminogen activator [tPA]) in a routine clinical setting.Methods: A total of 109 consecutive intravenous thrombolysis patients were prospectively included in the study. Recruitment concluded with 100 complete data sets. Before therapy, BW was estimated independently by 2 physicians, 2 emergency nurses, and a neuroradiological technical assistant. Patients were weighed, and anthropometric measurements for BW approximation were taken. Dosing errors were assessed. Clinical outcome was evaluated at 90 days.Results: Of 109 patients, 55 (50.5%) were unable to provide information on their BW. Of those, 11 (20%) were accompanied by relatives able to give BW information. For all patients, estimation errors rates ranged from 20.8% (patient's own estimation) up to 38.2% (treating physician) and 42.2% (emergency nurse). Finally, 29 patients received an Alteplase dosage diverging >10% from the optimal dose. Twelve were under- and 17 overdosed. Underdosage was an independent predictor for worse outcome in multivariate analysis.Conclusions: Our study shows that reliable BW data are missing for a majority of intravenous thrombolysis patients. Measuring BW before administering Alteplase remains challenging. Given dosing errors in one-third of patients and the observed impact on outcome, standardized weighing before thrombolysis should be considered. Clinical Trial Registration-URL: http://www.clinicaltrials.gov. Unique identifier: NCT01006434.
      pubtype: Academic Journal
      doctype:
        research
        Journal Article
      ougenre: Article
    language: English
    refInfo:
    holdings:
      @attributes:
        islocal: N